Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults.
Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults.
复制标题
摄入枯草芽孢杆菌DE111可改善健康成人的血脂和内皮功能。
DOI：
10.3920/bm2020.0039
复制
发表时间：
2020-11-15
影响因子：
5.4
通讯作者：
Weir TL
中科院分区：
文献类型：
--
作者：
Trotter RE;Vazquez AR;Grubb DS;Freedman KE;Grabos LE;Jones S;Gentile CL;Melby CL;Johnson SA;Weir TL
心血管疾病（CVD）是美国和世界范围内的主要死亡原因。到2030年，预计CVD将夺走超过2400万人的生命。在过去的十年中，研究人员研究了肠道微生物群在CVD发展中的作用。有证据表明双歧杆菌与血管功能、葡萄糖耐量和减少全身炎症呈正相关。另一种益生菌，枯草芽孢杆菌，也被发现可以降低人类和动物模型中的胆固醇水平。根据这些数据，我们研究了食用动物双歧杆菌亚种后心血管健康的各种措施。乳酸菌菌株BL 04，有和没有大肠杆菌靶向噬菌体（以PreforPro销售）、枯草芽孢杆菌菌株DE 111或基于麦芽糖糊精的安慰剂的混合物。在一项随机、双盲、安慰剂对照的为期4周的干预研究中，对18至65岁、体重指数为20至34.9的个体进行了干预，我们发现，在摄入B的个体中，测得的CVD参数没有显著变化。有或没有噬菌体。然而，B。与基线测量值相比，补充枯草杆菌导致总胆固醇（−8 mg/dl; P=0.04，置信区间（CI）：−13.40，−0.19）以及非高密度脂蛋白胆固醇（−11 mg/dl; P=0.01，CI：−12.43，−2.07）显著降低。此外，我们观察到内皮功能（P=0.05，CI：-0.003，0.370）和低密度脂蛋白胆固醇（P=0.06，CI：-12.29，0.2864）的趋势改善。引人注目的是，这些影响在一个基本健康的人群中看到。这些数据表明，B。补充枯草杆菌可能有益于改善与CVD相关的风险因素。需要在老年人或血脂异常和内皮功能障碍人群中进行进一步研究。
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide. By 2030 it is anticipated that CVD will claim the lives of more than 24 million people. Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of CVD. Evidence exists for a positive correlation between Bifidobacterium and vascular function, glucose tolerance, and reduced systemic inflammation. Another probiotic species, Bacillus subtilis, has also been found to reduce cholesterol levels in human and animal models. In light of these data, we examined various measures of cardiovascular health after consumption of Bifidobacterium animalis subsp. lactis strain BL04, with and without a cocktail of Escherichia coli-targeting bacteriophages (marketed as PreforPro), Bacillus subtilis strain DE111 or a maltodextrin-based placebo in a healthy human population. In a randomised, double-blind, placebo-controlled 4-week intervention conducted in individuals 18 to 65 years of age with a body mass index of 20 to 34.9, we saw no significant changes in measured CVD parameters among individuals consuming B. lactis with or without bacteriophages. However, B. subtilis supplementation resulted in a significant reduction in total cholesterol relative to baseline measures (−8 mg/dl; P=0.04, confidence interval (CI): −13.40, −0.19), as well as non-high-density lipoprotein-cholesterol (−11 mg/dl; P=0.01, CI: −12.43, −2.07). In addition we observed trending improvements in endothelial function (P=0.05, CI: −0.003, 0.370) and in low-density lipoprotein-cholesterol (P=0.06, CI: −12.29, 0.2864). Strikingly, these effects were seen in a largely healthy population. These data suggest that B. subtilis supplementation may be beneficial for improving risk factors associated with CVD. Further studies in populations of older adults or those with dyslipidaemia and endothelial dysfunction is warranted.